ArticleJournal of translational medicine2026

The immunological fitness of NSCLC patients drives the response to anti-PD1-based immunotherapy regardless of age.

Lucrezia Tuosto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.